Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.
Subclinical atherosclerosis, referring to plaque or coronary artery calcification (CAC), is still present in almost half of middle-aged adults free of standard modifiable cardiovascular risk factors (CVRFs) such as hypertension, diabetes, and high LDL cholesterol (LDL-C), reveals the prospective observational PESA* study.
A higher dose of pitavastatin can benefit Japanese patients with stable coronary artery disease (CAD) compared with a low-dose pitavastatin, even though cardiovascular (CV) event incidence is known to be lower in Asian than Western patients, according to the REAL-CAD study presented at the AHA Scientific Sessions 2017.
Long-term statin use was associated with an almost 30 percent increased risk of type 2 diabetes (T2D) in patients who were already at high risk of developing the disease, according to results from the DPP* and DPPOS**.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final results of the EXCEL* trial presented at TCT 2019.